Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib Rollover Study
NCT04949191Phase 2
Key facts
- Status
- Terminated
- Start
- Jul 2021
- Primary completion
- Apr 2024
- Countries
- 4
- Sponsor
- Incyte
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Drugs
- pemigatinib
- Conditions
- malignant neoplasms (advanced stage)
01
Overview
Phase 2, open-label trial of pemigatinib in malignant neoplasms (advanced stage) (3 arms), sponsored by Incyte. Primary endpoint: Number of Participants With Any Treatment-emergent Adverse Event. Started Jul 2021; status: terminated.
02
Design
3 arms- Study design
- Non-randomizedOpen-label
Pemigatinib Monotherapy
Pemigatinib orally once daily
Pemigatinib + Retifanlimab
Pemigatinib daily + Retifanlimab q4w
Pemigatinib + Pembrolizumab
Pemigatinib daily + Pembrolizumab
03
Who it enrols
Patients currently enrolled in an Incyte-sponsored study of pemigatinib who are benefiting from treatment and have no progressive disease.
04
Endpoints
Primary
Number of Participants With Any Treatment-emergent Adverse Event
Beyond the preview
Go deeper on NCT04949191.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04949191.